AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 616840380
Drug: Intraorbital electroacupuncture
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraorbital electroacupuncture therapy
Trial: 616840380
Drug: Neural nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural nutrition drug (given to both groups)
Trial: 35122085
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use >60 days/year
Trial: 35493824
Drug: t-DCS (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t-DCS (n = 13) for 5 daily sessions (20 min−2 mA) with bi-hemispheric stimulation over the primary motor cortex (M1)
Trial: 32345452
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with suboccipital muscle inhibition and interferential current (20 minutes, twice weekly for 4 weeks)
Trial: 33633687
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in daily GH dose (IGF-1 target level of 1 to 2 SDS)
Trial: 33633687
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in daily GH dose (IGF-1 target level of -2 to -1 SDS)
Trial: 35535532
Drug: Eperisone hydrochloride
RxNorm normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eperisone hydrochloride tablets combined with TSLO brace, oral eperisone hydrochloride tablets 50 mg three times a day, wearing TSLO brace for not less than 8 hours a day for 4 weeks.
Trial: 36209441
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms
Trial: 35114667
Drug: CoronaVac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoronaVac vaccine (group A1)
Trial: 33270038
Drug: Pro-vaccine posts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro-vaccine posts (n=324)
Trial: 33270038
Drug: Anti-vaccine posts
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-vaccine posts (n=256)
Trial: 33270038
Drug: Most liked
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Most liked pro-vaccine post
Trial: 33223228
Drug: 5% Lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Lidocaine Patch (LP)
Trial: 35307066
Drug: NCPAP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCPAP combined with inhalation of pulmonary surfactant using vibrating mesh nebulizers
Trial: 35307066
Drug: NCPAP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCPAP combined with inhalation of pulmonary surfactant using endotracheal tube (INSURE)
Trial: 34344839
Drug: Octenidine solution
RxNorm normalized name: octenidine
DrugBank: Octenidine (DB12624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidine solution
Trial: 35050943
Drug: Weierkang pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weierkang pills
Trial: 34419090
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of colostrum
Trial: 32467546
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (Metformin/Glibenclamide 500mg/5mg)
Trial: 32467546
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (Metformin/Glibenclamide 500mg/5mg)
Trial: 33511201
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3 g of TXA in 100 mL saline after TKA)
Trial: 33511201
Drug: Topical Floseal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Floseal® (10 mL of Floseal® intra-articularly during surgery)
Trial: 33511201
Drug: Placebo (intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intra-articular saline injection only)
Trial: 32420786
Drug: Curcumin (500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500-mg capsules twice daily)
Trial: 33880813
Drug: Purslane extract
RxNorm normalized name: purslane extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purslane extract (300 mg/day)
Trial: 32562683
Drug: Dulaglutide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (1.5 mg, subcutaneous injections once a week)
Trial: 33333295
Drug: All tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All tralokinumab doses
Trial: 35578315
Drug: Self-management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management of sedative therapy with dexmedetomidine
Trial: 33884617
Drug: Dialectical behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behaviour therapy (DBT)
Trial: 33573926
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg methylprednisolone
Trial: 36949478
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT)
Trial: 35118740
Drug: Auricular acupuncture
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupuncture (AA) treatment for 8 weeks
Trial: 34390762
Drug: Omarigliptin (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omarigliptin (once-weekly DPP-4 inhibitor)
Trial: 34390762
Drug: Once-daily DPP-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily DPP-4 inhibitors (control)
Trial: 34031050
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) treatment
Trial: 36443540
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments
Trial: 33396403
Drug: Food frequency
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food frequency questionnaire used to calculate food variety and food group diversity scores; low fruit and vegetable consumption: 24–47 months; 63.8 g (girls), 69.5 g (boys); 48–60 months; 68.3 g (girls), 74.4 g (boys); p = 0.037 (24–47 months), p = 0.038 (48–60 months)
Trial: 32676727
Drug: Magnetic sphincter
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic sphincter augmentation (MSA)
Trial: 39217573
Drug: Aspirin monotherapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin monotherapy
Trial: 35914511
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Clopidogrel
Trial: 34495376
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg every day)
Trial: 38353301
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg)
Trial: 36157208
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus laparoscopic radical hysterectomy
Trial: 36157208
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus open radical hysterectomy (control group)
Trial: 34998900
Drug: Palliative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative chemotherapy (CT)
Trial: 34636899
Drug: Burosumab therapy
RxNorm normalized name: Burosumab
DrugBank: Burosumab (DB14012)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Burosumab therapy
Trial: 33872197
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus fish skin graft applied weekly for up to 12 weeks
Trial: 32728703
Drug: Integrase strand
RxNorm normalized name: Integrase strand transfer inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrase strand transfer inhibitor (InSTI) resistance testing
Trial: 32728703
Drug: Reverse transcriptase
RxNorm normalized name: Reverse transcriptase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reverse transcriptase inhibitor and PI resistance testing
Trial: 35947524
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (HDDT): amoxicillin 750 mg q.i.d. and esomeprazole 40 mg t.i.d.
Trial: 35947524
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clarithromycin-containing bismuth quadruple therapy (ACBQT): esomeprazole 20 mg, bismuth potassium citrate 2 g, amoxicillin 1 g, and clarithromycin 500 mg; b.i.d.
Trial: 33960071
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation (PMR) exercises, twice weekly for 8 weeks
Trial: 37621153
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg/day
Trial: 33004727
Drug: Group Motivational
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Motivational Therapy (GMT)
Trial: 33004727
Drug: Individualised Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised Motivational Therapy (IMT)
Trial: 33851429
Drug: Dopamine agonists
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonists
Trial: 34540188
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 ?g/kg loading dose for 15 min, followed by 0.4 ?g/kg/h until 30 min before surgery)
Trial: 34540188
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline administered in the same manner)
Trial: 34878707
Drug: Neostigmine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 50 µg/kg
Trial: 34680123
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) adjunctive therapy (16 mg/mL cross-linked and 2 mg/mL non-cross-linked)
Trial: 34680123
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-surgical periodontal therapy without HA)
Trial: 32483134
Drug: Atorvastatin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (single 80-mg oral dose)
Trial: 32304405
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (50 mg/kg loading dose for 15 min, followed by 15 mg · kg · h infusion)
Trial: 39135452
Drug: Tofacitinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib treatment
Trial: 35384093
Drug: Liberal oral
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal oral intake immediately after discharge from PACU
Trial: 35384093
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral intake 6 hours after discharge from PACU
Trial: 35384093
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral intake
Trial: 35384093
Drug: Liberal oral
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal oral intake
Trial: 32555601
Drug: True-immunized subjects
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True-immunized subjects administered three booster immunizations
Trial: 32116251
Drug: Genetically DBP
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically DBP levels (per 1 standard deviation (SD) increase 50 mg/L)
Trial: 33717194
Drug: Zika purified-inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zika purified-inactivated virus (ZPIV) vaccine, 3 doses
Trial: 33717194
Drug: Zika purified-inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zika purified-inactivated virus (ZPIV) vaccine in JEV pre-immunized individuals
Trial: 33717194
Drug: Zika purified-inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zika purified-inactivated virus (ZPIV) vaccine in YFV pre-immunized individuals
Trial: 33717194
Drug: Zika purified-inactivated
RxNorm normalized name: Purified inactivated SARS-CoV-2 Vaccine
DrugBank: BBIBP-CorV (DB15807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zika purified-inactivated virus (ZPIV) vaccine in flavivirus-naïve individuals
Trial: 35490585
Drug: Ultrasound-guided stellate
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided stellate ganglion injection
Trial: 34794202
Drug: CitruSlim high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CitruSlim high-dose (HD, 400 mg)
Trial: 34794202
Drug: CitruSlim low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CitruSlim low-dose (LD, 200 mg)
Trial: 39532861
Drug: Ad26.COV2.S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.COV2.S vaccine
Trial: 32443348
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block with periarticular infiltration (30 mL of 0.5% ropivacaine and 100 mcg of clonidine)
Trial: 631335334
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (control group)
Trial: 34685778
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control)
Trial: 33896333
Drug: M7583 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M7583 at 80 mg (three days)/160 mg (full 28-day cycle), then 300 mg/day, 600 mg/day, 900 mg/day, and 300 mg twice daily
Trial: 34716710
Drug: Dialogic book‐sharing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialogic book‐sharing (8 weekly group sessions)
Trial: 33878282
Drug: Deprescribing anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprescribing anticholinergic medications (ACM) over 1 to 6 months with education directed at psychiatrists and clinical pharmacy support.
Trial: 32527232
Drug: Glibenclamide (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (loading dose of 1.25 mg, followed by 0.625 mg every 8 hours for 5 days)
Trial: 35831850
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (80 mg daily)
Trial: 35151410
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 24 weeks)
Trial: 35291004
Drug: High-dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE)
Trial: 37148831
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) therapy
Trial: 34438469
Drug: High-dose colchicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose colchicine
Trial: 34534800
Drug: 7-day internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day internet-based cognitive behavioral therapy (CBT)
Trial: 34432514
Drug: Hydromorphone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.1 mg/kg, IM) alone (group H)
Trial: 34432514
Drug: Hydromorphone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.1 mg/kg, IM) with acepromazine (0.05 mg/kg, IM; group AH)
Trial: 34432514
Drug: Hydromorphone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (0.1 mg/kg, IM) with dexmedetomidine (6 µg/kg, IM; group DH)
Trial: 37808864
Drug: Losartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan treatment
Trial: 38281309
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg
Trial: 33792958
Drug: Fluoxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40 mg/d)
Trial: 33268419
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous zinc (0.5 mg/kg)
Trial: 36336851
Drug: Corticosteroid irrigation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid irrigation, Saline irrigation, No treatment
Trial: 37140175
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT)
Trial: 32713395
Drug: Nocturnal whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal whey protein ingestion (63 g whey protein)
Trial: 35279338
Drug: Custom group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom group (alternative drugs based on pharmacogenetic testing)
Trial: 34452970
Drug: CORKA (Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORKA (Community Rehabilitation after Knee Arthroplasty) home‐based rehabilitation, receiving a median five treatment sessions (IQR 4‐7)
Trial: 36327275
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous butylscopolamine bromide
Trial: 36327275
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo (1 mL sodium chlorine 9 mg/mL)
Trial: 32125929
Drug: ATRIPLA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATRIPLA + rosemary methanolic extract (400 mg/day)
Trial: 32208397
Drug: Prasugrel 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 3.75 mg (PRA3.75)
Trial: 32208397
Drug: Prasugrel 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 2.5 mg (PRA2.5)
Trial: 32208397
Drug: Clopidogrel 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 50 mg (CLO50)
Trial: 34872404
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg for 7 days
Trial: 35905752
Drug: Dolutegravir-based regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir-based regimen (50 mg dolutegravir, 300 mg tenofovir disoproxil fumarate, and either 200 mg emtricitabine in South Africa or 300 mg lamivudine in Uganda)
Trial: 35905752
Drug: Efavirenz-based regimen
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based regimen (fixed dose combination 600 mg tenofovir disoproxil fumarate plus either emtricitabine in South Africa or lamivudine in Uganda)
Trial: 36116413
Drug: MP2/cc‐pVTZ method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP2/cc‐pVTZ method to calculate the Raman spectra of serine conformers
Trial: 32926799
Drug: Curcuma longa
RxNorm normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma longa extract (CL) 2 capsules per day for 12 weeks
Trial: 32926799
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo 2 capsules per day for 12 weeks
Trial: 34298589
Drug: Dipyridamole plus
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole plus aspirin
Trial: 35614473
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg codeine
Trial: 35614473
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg codeine
Trial: 34875345
Drug: Bifidobacterium breve
RxNorm normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium breve CCFM1025 (10^10 CFU daily for 4 weeks)
Trial: 33658293
Drug: Placebo vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaccine
Trial: 33142510
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vitamin E and omega-3 fatty acids during the starter phase (0-10 d)